In a report released today, Rajan Sharma from Goldman Sachs reiterated a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s shares closed yesterday at $10.87.
According to TipRanks, Sharma is an analyst with an average return of -15.0% and a 37.93% success rate. Sharma covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Zealand Pharma, and Roivant Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $16.86 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $13.24 and a one-year low of $6.59. Currently, Roivant Sciences has an average volume of 5.44M.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roivant Sciences (ROIV) Company Description:
Montes Archimedes Acquisition Corp is a blank check company.
Read More on ROIV:
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- ROIV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jefferies ‘encouraged thus far’ by Arbutus patent hearing
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
